ARTICLE | Company News

Cell Medica acquiring Delenex

July 13, 2016 12:47 AM UTC

Cell Medica Ltd. (London, U.K.) is acquiring Delenex Therapeutics AG (Zurich, Switzerland) for undisclosed terms. Cell Medica plans to use Delenex's PENTRA antibody fragment platform to develop next-generation chimeric antigen receptor (CAR)-modified cellular immunotherapies. Delenex's operations will be renamed Cell Medica Switzerland AG and integrated into Cell Medica's global R&D operations. ...